<DOC>
	<DOCNO>NCT02331277</DOCNO>
	<brief_summary>The primary objective trial investigate safety tolerability multiple dos BI 655064 follow weekly subcutaneous injection 4 week healthy Chinese male volunteer . The secondary objective exploratory evaluation pharmacokinetics pharmacodynamics multiple dos BI 655064 follow weekly subcutaneous injection 4 week healthy Chinese male volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetics Multiple Doses BI 655064 Healthy Chinese Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male accord investigator 's assessment , base follow criterion : complete medical history include physical examination , vital sign ( Blood pressure , Pulse rate ) , 12lead Echocardiogram , clinical laboratory test 2 . Chinese ethnicity accord follow criterion : Ethnic Chinese , born China ethnic Chinese born outside China , descendent 4 ethnic Chinese grandparent bear China 3 . Age within range 20 45 year inclusive 4 . Body Mass Index within range 18.5 25 kg/m2 inclusive 5 . Signed date write informed consent prior admission study accordance GCP local legislation 6 . Male subject document sterile consistently correctly use condom female partner ( childbearing potential ) agree use follow adequate contraception method : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) date screen least 6 month last dose BI 655064 take current trial . donate sperm sample procreation purpose , date screening least 6 month last dose BI 655064 take current trial . It responsibility male subject ensure partner become pregnant study duration . Exclusion criterion : 1 . Any finding medical examination ( include Blood pressure , Pulse rate Echocardiogram ) deviate normal judge clinically relevant investigator 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Any evidence concomitant disease judge clinically relevant investigator 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder 6 . History relevant orthostatic hypotension , faint spell , blackouts 7 . History relevant allergy/hypersensitivity ( include allergy trial medication excipients ) 8 . Intake drug long halflife ( &gt; 24 hour ) within 30 day less 10 halflives respective drug prior administration trial medication 9 . Within 10 day prior administration trial medication , use drug might reasonably influence result trial 10 . Participation another trial investigational drug administration within 60 day prior administration trial medication 11 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 12 . Inability refrain smoke trial day 13 . Alcohol abuse ( consumption 20 g/day ) 14 . Drug abuse positive drug screen 15 . Blood donation ( 100 mL within 30 day prior administration trial medication intend trial ) 16 . Intention commence new exercise regimen excessive physical activity within one week prior administration trial medication trial 17 . Inability comply protocol requirement ( include dietary regimen trial site ) assess investigator 18 . A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) screen examination 19 . Positive result infectious serology ( Hepatitis B Surface Antigen , Hepatitis B Core Antibody , Hepatitis C Antibody Human Immunodeficiency Virus ) screen examination 20 . History tuberculosis infection and/or positive Quantiferon TuberculosisGold test screen examination 21 . Abnormal result coagulation value indicate increase risk bleed thromboembolism complicate safety evaluation study determine investigator screen examination 22 . Subjects investigator 's judgement perceive excessive risk thromboembolism example personal history and/or first degree relative personal history onset age 55 significant thromboembolism , include limited deep vein thrombosis , pulmonary embolism , cortical sinus thrombosis , coronary cerebrovascular event , peripheral arterial insufficiency . 23 . Deficiency antithrombin III protein S protein C screen examination 24 . Prolongation bleed time reference range screen examination 25 . Subject assessed investigator unsuitable inclusion e.g . consider able understand comply study requirement condition would allow safe participation study</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>